Contact
searchSearch
HMP Global

Parkinson Disease News

An illustration of a brain with a puzzle piece missing, surrounded by doctors with elderly patients
News
In Early Trial, Ambroxol Shows Promise for Parkinson Disease Dementia
09/02/2025
Jolynn Tumolo
A drug used in Europe for treating respiratory conditions was safe, well-tolerated, and demonstrated target engagement in patients with Parkinson disease dementia (PDD).
A drug used in Europe for treating respiratory conditions was safe, well-tolerated, and demonstrated target engagement in patients with Parkinson disease dementia (PDD).
A drug used in Europe for...
09/02/2025
Neurology
A set of cycling bikes at the gym
News
Long-Term Exercise Significantly Modifies Neuronal Activity in Patients With PD
08/11/2025
Jolynn Tumolo
Patients with Parkinson disease (PD) demonstrated measurable changes in brain signals associated with motor control and movement after 12 sessions of dynamic cycling over a 4-week period.
Patients with Parkinson disease (PD) demonstrated measurable changes in brain signals associated with motor control and movement after 12 sessions of dynamic cycling over a 4-week period.
Patients with Parkinson disease...
08/11/2025
Neurology
behavioral therapy
News
Behavioral Therapy Noninferior to Drug Therapy in Treating Overactive Bladder Symptoms in Patients With PD
07/17/2025
Maria Mantas
Behavioral therapy is noninferior to drug therapy in improving overactive bladder (OAB) symptoms in patients with Parkinson disease (PD), according to a recent study published in JAMA Neurology.
Behavioral therapy is noninferior to drug therapy in improving overactive bladder (OAB) symptoms in patients with Parkinson disease (PD), according to a recent study published in JAMA Neurology.
Behavioral therapy is...
07/17/2025
Neurology
An illustrated picture shows two cartoon doctors, one holding up a magnifying glass to a cartoon brain.
News
α-Synuclein Seed Amplification Assay Kinetic Measures Offer Diagnostic, Prognostic Value in PD
06/30/2025
Jolynn Tumolo
Assessing cerebrospinal fluid (CSF) α-synuclein seed amplification assay measures could help differentiate Parkinson disease (PD) from progressive supranuclear palsy with Lewy body co-pathology.
Assessing cerebrospinal fluid (CSF) α-synuclein seed amplification assay measures could help differentiate Parkinson disease (PD) from progressive supranuclear palsy with Lewy body co-pathology.
Assessing cerebrospinal fluid...
06/30/2025
Neurology
an illustration of a brain and a colon
News
Cognitive Impairment in Parkinson Disease Linked to Mouth and Gut Bacteria
06/10/2025
Brionna Mendoza
A new study has identified a link between the progression of cognitive impairment in Parkinson disease and the bacteria residing in the mouth and the gut.
A new study has identified a link between the progression of cognitive impairment in Parkinson disease and the bacteria residing in the mouth and the gut.
A new study has identified a...
06/10/2025
Neurology
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
An illustration of a brain against a blue background, with a deep brain stimulation device connected via electrodes
News
FDA Approves ‘Self-Adjusting’ DBS Therapy for Parkinson Disease
02/25/2025
Brionna Mendoza
On Monday, the United States Food and Drug Administration (FDA) approved an adaptive deep brain stimulation (aDBS) technology for people living with Parkinson disease (PD).
On Monday, the United States Food and Drug Administration (FDA) approved an adaptive deep brain stimulation (aDBS) technology for people living with Parkinson disease (PD).
On Monday, the United States...
02/25/2025
Neurology
fda building sign
News
FDA Approves Apomorphine Drug-Device for Movement Symptoms in Parkinson Disease
02/04/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) approved a drug-device combination to treat movement-related symptoms in advanced Parkinson disease.
The US Food and Drug Administration (FDA) approved a drug-device combination to treat movement-related symptoms in advanced Parkinson disease.
The US Food and Drug...
02/04/2025
Neurology
a patient with parkinson disease steadies a tremoring hand and wrist
News
Propranolol Reduces Tremors in Parkinson Disease Patients
01/16/2025
Jolynn Tumolo
The beta-blocker propranolol reduces Parkinson disease (PD) tremor in both stressful and resting conditions, according to results from a placebo-controlled crossover trial published in the Annals of Neurology.
The beta-blocker propranolol reduces Parkinson disease (PD) tremor in both stressful and resting conditions, according to results from a placebo-controlled crossover trial published in the Annals of Neurology.
The beta-blocker propranolol...
01/16/2025
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
Meagan Thistle
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology

Migraine CME Series

News

FDA approval stamp
News
FDA Approves Subcutaneous Injection for Maintenance Treatment of Early AD
09/11/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once-weekly subcutaneous lecanemab-irmb injections (LEQEMBI IQLIK) for the maintenance treatment of early Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once-weekly subcutaneous lecanemab-irmb injections (LEQEMBI IQLIK) for the maintenance treatment of early Alzheimer disease (AD).
The US Food and Drug...
09/11/2025
Neurology
brain scan
News
Moderate to Severe TBI Linked With Development of Malignant Brain Tumors
09/08/2025
Jolynn Tumolo
A history of moderate to severe traumatic brain injury (TBI) in US adult civilians was associated with an increased risk of developing a malignant brain tumor over follow-up.
A history of moderate to severe traumatic brain injury (TBI) in US adult civilians was associated with an increased risk of developing a malignant brain tumor over follow-up.
A history of moderate to severe...
09/08/2025
Neurology
A woman lies in bed with her mouth open snoring sleep apnea
News
New AASM Patient-Reported Outcome Tool Valid for Monitoring Sleep Apnea
09/08/2025
Jolynn Tumolo
A patient-reported outcome tool developed by the American Academy of Sleep Medicine (AASM) is clinically valid, reliable, and feasible for monitoring treatment response and longitudinal symptom progression in adults with obstructive sleep...
A patient-reported outcome tool developed by the American Academy of Sleep Medicine (AASM) is clinically valid, reliable, and feasible for monitoring treatment response and longitudinal symptom progression in adults with obstructive sleep...
A patient-reported outcome tool...
09/08/2025
Neurology
Mediterranean diet
News
Mediterranean Diet May Mitigate Genetic Risk for Alzheimer Disease
09/05/2025
Brionna Mendoza
For those carrying the APOE4 gene, following a Mediterranean diet may lower the risk of developing Alzheimer disease and dementia, suggest study results published in Nature Medicine.
For those carrying the APOE4 gene, following a Mediterranean diet may lower the risk of developing Alzheimer disease and dementia, suggest study results published in Nature Medicine.
For those carrying the APOE4...
09/05/2025
Neurology
An illustration of a brain with a puzzle piece missing, surrounded by doctors with elderly patients
News
In Early Trial, Ambroxol Shows Promise for Parkinson Disease Dementia
09/02/2025
Jolynn Tumolo
A drug used in Europe for treating respiratory conditions was safe, well-tolerated, and demonstrated target engagement in patients with Parkinson disease dementia (PDD).
A drug used in Europe for treating respiratory conditions was safe, well-tolerated, and demonstrated target engagement in patients with Parkinson disease dementia (PDD).
A drug used in Europe for...
09/02/2025
Neurology
A head in profile with cogs coming out of it against an orange background
News
Less Than a Third of Patients With Focal Epilepsy Become Seizure-Free on First ASM
08/26/2025
Jolynn Tumolo
Most patients with newly diagnosed focal epilepsy require more than 1 antiseizure medication (ASM) and more than 1 year to achieve seizure freedom.
Most patients with newly diagnosed focal epilepsy require more than 1 antiseizure medication (ASM) and more than 1 year to achieve seizure freedom.
Most patients with newly...
08/26/2025
Neurology
A teddy bear against a blue background wearing a mask and stethoscope.
News
Phase 2 Trial Finds Risdiplam Effective and Safe in Newborns With SMA
08/21/2025
Jolynn Tumolo
Infants with presymptomatic spinal muscular atrophy (SMA) treated with risdiplam as early as 16 days of age had better functional and survival outcomes at 12 and 24 months compared with untreated infants with SMA.
Infants with presymptomatic spinal muscular atrophy (SMA) treated with risdiplam as early as 16 days of age had better functional and survival outcomes at 12 and 24 months compared with untreated infants with SMA.
Infants with presymptomatic...
08/21/2025
Neurology
brain scans
News
Early Intravenous Immunoglobulins May Improve Outcomes in Anti-IgLON5 Disease
08/18/2025
Jolynn Tumolo
Starting intravenous immunoglobulins within the first year of anti-IgLON5 disease onset was associated with better outcomes and fewer deaths over follow-up, according to study results published in JAMA Neurology.
Starting intravenous immunoglobulins within the first year of anti-IgLON5 disease onset was associated with better outcomes and fewer deaths over follow-up, according to study results published in JAMA Neurology.
Starting intravenous...
08/18/2025
Neurology
A woman lies in bed awake due to insomnia
News
Cannabinoids Produce Worse Sleep Outcomes in Small Pilot Study
08/15/2025
Brionna Mendoza
A single dose of tetrahydrocannabinol/cannabidiol (THC/CBD) resulted in worse sleep for study participants with insomnia.
A single dose of tetrahydrocannabinol/cannabidiol (THC/CBD) resulted in worse sleep for study participants with insomnia.
A single dose of...
08/15/2025
Neurology
child sitting at a desk
News
Oseltamivir Reduces Risk of Serious Neuropsychiatric Events in Children During Influenza Episodes
08/13/2025
Maria Mantas
Oseltamivir treatment was associated with a reduction in serious neuropsychiatric events in children and adolescents during influenza episodes, according to cohort study results published in JAMA Neurology. 
Oseltamivir treatment was associated with a reduction in serious neuropsychiatric events in children and adolescents during influenza episodes, according to cohort study results published in JAMA Neurology. 
Oseltamivir treatment was...
08/13/2025
Neurology

Alzheimer's Disease CME Series

Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use